JPH09504961A - 異種ペプチドのベクターとしての改質植物ウイルス - Google Patents
異種ペプチドのベクターとしての改質植物ウイルスInfo
- Publication number
- JPH09504961A JPH09504961A JP8504789A JP50478996A JPH09504961A JP H09504961 A JPH09504961 A JP H09504961A JP 8504789 A JP8504789 A JP 8504789A JP 50478996 A JP50478996 A JP 50478996A JP H09504961 A JPH09504961 A JP H09504961A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- plant
- particle according
- heterologous peptide
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 109
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 239000013598 vector Substances 0.000 title claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title description 20
- 239000002245 particle Substances 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 31
- 229960005486 vaccine Drugs 0.000 claims abstract description 10
- 241000196324 Embryophyta Species 0.000 claims description 74
- 241000723655 Cowpea mosaic virus Species 0.000 claims description 58
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 40
- 230000003612 virological effect Effects 0.000 claims description 33
- 101710132601 Capsid protein Proteins 0.000 claims description 32
- 108091034117 Oligonucleotide Proteins 0.000 claims description 26
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 22
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 239000002299 complementary DNA Substances 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 241001465754 Metazoa Species 0.000 claims description 17
- 101710094648 Coat protein Proteins 0.000 claims description 16
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 16
- 101710125418 Major capsid protein Proteins 0.000 claims description 16
- 101710141454 Nucleoprotein Proteins 0.000 claims description 16
- 101710083689 Probable capsid protein Proteins 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 13
- 108091008146 restriction endonucleases Proteins 0.000 claims description 12
- 241000430519 Human rhinovirus sp. Species 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 210000001938 protoplast Anatomy 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 6
- 238000011081 inoculation Methods 0.000 claims description 6
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 241000723607 Comovirus Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 241001493065 dsRNA viruses Species 0.000 claims description 4
- 230000002163 immunogen Effects 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 2
- 239000000813 peptide hormone Substances 0.000 claims description 2
- 244000037640 animal pathogen Species 0.000 claims 2
- 241000701931 Canine parvovirus Species 0.000 claims 1
- 241000701489 Cauliflower mosaic virus Species 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 claims 1
- 230000008827 biological function Effects 0.000 claims 1
- 244000052637 human pathogen Species 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 description 25
- 239000000047 product Substances 0.000 description 17
- 238000006386 neutralization reaction Methods 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000003472 neutralizing effect Effects 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 241000219977 Vigna Species 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 238000010276 construction Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 210000002845 virion Anatomy 0.000 description 6
- 235000010726 Vigna sinensis Nutrition 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 101100135798 Caenorhabditis elegans pcp-1 gene Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 3
- 108010017826 DNA Polymerase I Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101100135809 Mus musculus Pcp2 gene Proteins 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 101150052859 Slc9a1 gene Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 241001524679 Escherichia virus M13 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- -1 eg For example Proteins 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 101710114816 Gene 41 protein Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101800000316 Movement protein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020005120 Plant DNA Proteins 0.000 description 1
- 108020005089 Plant RNA Proteins 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 101100244390 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PMT7 gene Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 101800000874 Small capsid protein Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
- C12N15/8203—Virus mediated transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 植物ウイルスのコートタンパク質中に異種ペプチドインサートを含む植 物ウイルスの集合粒子であって、インサートの部位がインサートに隣接する直列 反復配列を含まないことを特徴とする、集合粒子。 2. インサートがコートタンパク質の付加物である、請求の範囲第1項に記 載のウイルス粒子。 3. 異種ペプチドが生物学的機能を有するペプチドであり、この生物学的適 用には、より大きい分子または粒子と関連したペプチドの表示を必要としまたは これによって増強される、請求の範囲第1項または第2項に記載のウイルス粒子 。 4. ペプチドが抗原である、請求の範囲第1〜3項のいずれか1項に記載の ウイルス粒子。 5. 抗原がウイルス抗原である、請求の範囲第4項に記載のウイルス粒子。 6. 抗原が動物(ヒトを含む)のウイルス抗原である、請求の範囲第5項に 記載のウイルス粒子。 7. 異種ペプチドが植物ウイルスのコートタンパク質の露出表面に組み込ま れている、請求の範囲第1〜6項のいずれか1項に記載のウイルス粒子。 8. 植物ウイルスがRNAウイルスである、請求の範囲第1〜7項のいずれ か1項に記載のウイルス粒子。 9. ウイルスコートタンパク質がβ−バレル構造を有する、請求の範囲第1 〜8項のいずれか1項に記載のウイルス粒子。 10. 異種ペプチドが植物ウイルスのβシートに結合しているループに挿入 されている、請求の範囲第9項に記載のウイルス粒子。 11. 異種ペプチドが植物ウイルスのβシートに結合しているループのプロ リンまたはヒドロキシプロリン残基の次に挿入される、請求の範囲第10項に記 載のウイルス粒子。 12. 植物ウイルスがコモウイルスである、請求の範囲第1〜11項のいず れか1項に記載のウイルス粒子。 13. コモウイルスがササゲモザイクウイルス(CPMV)である、請求の 範囲第12項に記載のウイルス粒子。 14. 異種ペプチドが植物ウイルスのβB−βCループに挿入されている、 請求の範囲第9〜13項のいずれか1項に記載のウイルス粒子。 15. 異種ペプチドが口蹄疫ウイルス(FMDV)由来の動物ウイルス抗原 である、請求の範囲第1〜14項のいずれか1項に記載のウイルス粒子。 16. 異種ペプチドがヒト免疫不全ウイルス(HIV)由来の動物ウイルス 抗原である、請求の範囲第1〜14項のいずれか1項に記載のウイルス粒子。 17. 異種ペプチドがヒトライノウイルス(HRV)由来の動物ウイルス抗 原である、請求の範囲第1〜14項のいずれか1項に記載のウイルス粒子。 18. 異種ペプチドがイヌパルボウイルス由来の動物ウイルス抗原である、 請求の範囲第1〜14項のいずれか1項に記載のウイルス粒子。 19. 異種ペプチドがStaphylococcus aureus由来の動物病原体抗原である 、請求の範囲第1〜14項のいずれか1項に記載のウイルス粒子。 20. 異種ペプチドがペプチドホルモン由来の抗原である、請求の範囲第1 〜14項のいずれか1項に記載のウイルス粒子。 21. 異種ペプチドがゴナドトロピン放出ホルモン由来の抗原である、請求 の範囲第20項に記載のウイルス粒子。 22. 請求の範囲第4〜21項のいずれか1項に記載の集合植物ウイルス粒 子をその免疫原成分として含んでなる、ヒトまたは動物の病原体に対する防護ワ クチン。 23. 請求の範囲第6項に記載のウイルス粒子をその免疫原成分として含む 、 動物ウイルスワクチン。 24. 異種ペプチドをコードするヌクレオチド配列を導入して、コートタン パク質をコードする植物ウイルス核酸を修飾して、導入された配列に隣接する直 列反復配列の産生を回避するようにして、植物、植物組織、植物細胞、または原 形質体を、改質したウイルス核酸で感染させ、改質したウイルスの集合粒子を回 収することことを特徴とする、請求の範囲第1〜21項のいずれか1項に記載の 植物ウイルス粒子の製造法。 25. 導入されるヌクレオチド配列を、コートタンパク質の露出部分をコー ドする植物ウイルス核酸の部分に挿入する、請求の範囲第24項に記載の方法。 26. RNA植物ウイルスに適用される、請求の範囲第24項に記載の方法 であって、異種ペプチドをコードするDNA配列を、コートタンパク質の露出部 分をコードする植物ウイルスのRNAに相当するcDNAに導入し、このように 修飾したcDNAからRNA転写体を産生させ、植物、植物組織、植物細胞、ま たは原形質体に、転写体を、必要ならば植物材料中の全ウイルス粒子の増殖およ び集合に要する任意の他のRNAと一緒に接種し、改質ウイルスの集合粒子を回 収することを特徴とする、方法。 27. 異種ペプチドをコードするDNAを植物ウイルスcDNAから摘出さ れたDNAフラグメントに導入し、修飾フラグメントを組換えて植物ウイルスc DNAを改質形態に再構成することによって改質cDNAを産生させる、請求の 範囲第26項に記載の方法。 28. 植物ウイルス核酸の2種類の異なる制限酵素部位を選択し、相当する 制限酵素を用いて植物ウイルス核酸を切断し、切断したウイルス核酸に、異種ペ プチドをコードしかつ制限酵素切断部位と両立性の末端で終わる相補的オリゴヌ クレオチドの対を挿入することによって、異種ヌクレオチド配列を挿入する、請 求の範囲第24〜27項のいずれか1項に記載の方法。 29. 相補的オリゴヌクレオチドにおいて、異種ペプチドをコードする配列 に植物ウイルスに特異的な配列が隣接し、異種ヌクレオチドが植物ウイルス核酸 に対する付加物として挿入する、請求の範囲第28項に記載の方法。 30. 産生した改質ウイルス、またはそれから抽出されたRNAを植物に継 代して改質ウイルスを更に産生させる、請求の範囲第26項または第27項に記 載の方法。 31. cDNAが、構造体の5′末端に結合したカリフラワーモザイクウイ ルス35Sプロモーター配列を含む、請求の範囲第4〜29項のいずれか1項に 記載の方法。 32. コートタンパク質の露出表面に相当する部位で異種ペプチドをコード するDNA配列を含むCPMVコートタンパク質cDNAのフラグメントであっ て、前記部位がDNAインサートに隣接する直列反復配列を含まないことを特徴 とする、フラグメント。 33. SstIフラグメントである、請求の範囲第32項に記載のフラグメ ント。 34. 請求の範囲第32項または第33項に記載のフラグメントを含むベク ター。 35. CPMVのコートタンパク質の露出表面に対応する部位で異種ペプチ ドをコードするDNAインサートを含むCPMV M RNAの完全長cDNA を含んでなるベクターであって、前記部位がDNAインサートに隣接する直列反 復配列を含まないことを特徴とする、ベクター。 36. 請求の範囲第32〜35項のいずれか1項に記載のフラグメントまた はベクターのRNA転写体。 37. 請求の範囲第36項に記載のキャッピングしたRNA転写体。 38. 請求の範囲第22項または第23項に記載のワクチンを投与すること を特徴とする、病原体に対して動物(ヒトを含む)を防護する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9414118.1 | 1994-07-13 | ||
GB9414118A GB9414118D0 (en) | 1994-07-13 | 1994-07-13 | Modified plant viruses as vectors of heterologous peptides |
PCT/GB1995/001618 WO1996002649A1 (en) | 1994-07-13 | 1995-07-10 | Modified plant viruses as vectors of heterologous peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09504961A true JPH09504961A (ja) | 1997-05-20 |
JP3681753B2 JP3681753B2 (ja) | 2005-08-10 |
Family
ID=10758254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50478996A Expired - Fee Related JP3681753B2 (ja) | 1994-07-13 | 1995-07-10 | 異種ペプチドのベクターとしての改質植物ウイルス |
Country Status (16)
Country | Link |
---|---|
US (1) | US5958422A (ja) |
EP (1) | EP0719336B1 (ja) |
JP (1) | JP3681753B2 (ja) |
KR (1) | KR100379803B1 (ja) |
CN (1) | CN1211488C (ja) |
AT (1) | ATE346934T1 (ja) |
AU (1) | AU697867B2 (ja) |
BR (1) | BR9506047A (ja) |
CA (1) | CA2170412C (ja) |
CZ (1) | CZ290484B6 (ja) |
DE (1) | DE69535314T2 (ja) |
GB (1) | GB9414118D0 (ja) |
HU (1) | HU223078B1 (ja) |
NZ (1) | NZ289170A (ja) |
SK (1) | SK34296A3 (ja) |
WO (1) | WO1996002649A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003514775A (ja) * | 1999-10-14 | 2003-04-22 | ザ ダウ ケミカル カンパニー | 修飾された植物ウイルス及びその使用方法 |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660500B2 (en) | 1988-02-26 | 2003-12-09 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusions |
US5977438A (en) * | 1988-02-26 | 1999-11-02 | Biosource Technologies, Inc. | Production of peptides in plants as viral coat protein fusions |
US7033835B1 (en) | 1988-02-26 | 2006-04-25 | Large Scale Biology Corporation | Production of peptides in plants as viral coat protein fusions |
US6846968B1 (en) | 1988-02-26 | 2005-01-25 | Large Scale Biology Corporation | Production of lysosomal enzymes in plants by transient expression |
GB9108386D0 (en) * | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
US6034298A (en) * | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
US5484719A (en) | 1991-08-26 | 1996-01-16 | Edible Vaccines, Inc. | Vaccines produced and administered through edible plants |
US5612487A (en) * | 1991-08-26 | 1997-03-18 | Edible Vaccines, Inc. | Anti-viral vaccines expressed in plants |
AU6976296A (en) * | 1995-09-15 | 1997-04-01 | John A Howard | Expression cassettes and methods for delivery of animal vaccines |
GB9712282D0 (en) * | 1997-06-12 | 1997-08-13 | Innes John Centre Innov Ltd | Epitope presentation system |
US6759243B2 (en) | 1998-01-20 | 2004-07-06 | Board Of Trustees Of The University Of Illinois | High affinity TCR proteins and methods |
GB9921337D0 (en) * | 1999-09-09 | 1999-11-10 | Axis Genetics Plc | Modified plant viruses |
US7135282B1 (en) | 1999-10-14 | 2006-11-14 | The Dow Chemical Company | Viral particles with exogenous internal epitopes |
US6932980B1 (en) * | 2001-01-18 | 2005-08-23 | Richard Sayre | Method of making microalgal-based animal foodstuff supplements, microalgal-supplemented animal foodstuffs and method of animal nutrition |
US20030022359A1 (en) * | 2000-06-20 | 2003-01-30 | Sayre Richard T. | Transgenic algae for delivering antigens to an animal |
WO2002059334A1 (en) * | 2001-01-24 | 2002-08-01 | Virogene Ltd. | Vectors capable of imparting herbicide resistance and viral cross protection and methods |
US8101189B2 (en) * | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
JP4953570B2 (ja) * | 2002-07-05 | 2012-06-13 | フォリア バイオテック インコーポレイテッド | アジュバントウィルス粒子 |
EP3388521A1 (en) * | 2004-02-27 | 2018-10-17 | Dow AgroSciences LLC | High efficiency peptide production in plant cells |
WO2006124044A2 (en) * | 2004-07-30 | 2006-11-23 | George Mason University | Protein scaffolds and viral particles for detecting analytes |
WO2006093967A2 (en) * | 2005-02-28 | 2006-09-08 | The Scripps Research Institute | Compositions and methods for targeting or imaging a tissue in a vertebrate subject |
CA2608515A1 (en) * | 2005-06-01 | 2007-05-10 | Dow Global Technolgies Inc. | Production of multivalent virus like particles |
US20090117144A1 (en) * | 2005-07-19 | 2009-05-07 | Lada Rasochova | Recombinant flu vaccines |
WO2008058396A1 (en) * | 2006-11-15 | 2008-05-22 | Folia Biotech Inc. | Papaya mosaic virus-based vaccines for influenza |
EP1942188B1 (en) * | 2007-01-03 | 2009-12-23 | Academia Sinica | Recombinant viral proteins and particles |
CA2615372A1 (en) | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
JP2011509661A (ja) | 2007-11-27 | 2011-03-31 | メディカゴ インコーポレイテッド | ヘマグルチニンを発現するトランスジェニック植物において産生された組換え型インフルエンザウイルス様粒子(vlp) |
NZ590351A (en) | 2008-07-18 | 2012-11-30 | Medicago Inc | HA1 domain totally or partially free of N-linked glycosylation operatively linked to a regulatory region |
US20110206727A1 (en) * | 2008-07-30 | 2011-08-25 | Denis Leclerc | Multivalent Vaccines Based on Papaya Mosaic Virus and Uses Thereof |
US20100183523A1 (en) | 2009-01-22 | 2010-07-22 | Wagner Richard E | Dental composition and method |
HUE039100T2 (hu) | 2009-06-24 | 2018-12-28 | Medicago Inc | Hemagglutinint tartalmazó kimer influenzavírus-jellegû részecskék |
AU2010300033B2 (en) | 2009-09-22 | 2015-01-22 | Medicago Inc. | Method of preparing plant-derived VLPS |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
EP2568289A3 (en) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (en) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
JP6518257B2 (ja) | 2014-01-10 | 2019-05-22 | メディカゴ インコーポレイテッド | Cpmvエンハンサーエレメント |
EP3069730A3 (en) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US10617751B2 (en) | 2017-07-13 | 2020-04-14 | VisionTech International Limited | Edible vaccines expressed in yeast for preventing and treating infectious diseases in animals and humans |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8421282D0 (en) * | 1984-08-22 | 1984-09-26 | Connaught Lab | Multispecific antigenic proteins |
EP0999281A1 (en) * | 1988-02-26 | 2000-05-10 | Biosource Technologies, Inc. | Non-nuclear chromosomal transformation |
WO1991013994A1 (en) * | 1990-03-13 | 1991-09-19 | Commonwealth Scientific And Industrial Research Organisation | Gene expression |
EP0527767A4 (en) * | 1990-04-06 | 1993-05-05 | Commonwealth Scientific And Industrial Research Organisation | Self-polymerising expression system based on modified potyvirus coat proteins |
WO1993003161A1 (en) * | 1990-10-22 | 1993-02-18 | Biosource Genetics Corporation | Recombinant plant viral nucleic acids |
GB9108386D0 (en) * | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
WO1995021248A1 (en) * | 1994-02-03 | 1995-08-10 | The Scripps Research Institute | Method for using tobacco mosaic virus to overproduce peptides and proteins |
-
1994
- 1994-07-13 GB GB9414118A patent/GB9414118D0/en active Pending
-
1995
- 1995-07-10 SK SK342-96A patent/SK34296A3/sk unknown
- 1995-07-10 HU HU9600586A patent/HU223078B1/hu not_active IP Right Cessation
- 1995-07-10 US US08/612,858 patent/US5958422A/en not_active Expired - Fee Related
- 1995-07-10 AU AU28934/95A patent/AU697867B2/en not_active Ceased
- 1995-07-10 CN CNB951907956A patent/CN1211488C/zh not_active Expired - Fee Related
- 1995-07-10 CZ CZ1996723A patent/CZ290484B6/cs not_active IP Right Cessation
- 1995-07-10 DE DE69535314T patent/DE69535314T2/de not_active Expired - Lifetime
- 1995-07-10 JP JP50478996A patent/JP3681753B2/ja not_active Expired - Fee Related
- 1995-07-10 CA CA002170412A patent/CA2170412C/en not_active Expired - Fee Related
- 1995-07-10 BR BR9506047A patent/BR9506047A/pt not_active Application Discontinuation
- 1995-07-10 AT AT95924436T patent/ATE346934T1/de not_active IP Right Cessation
- 1995-07-10 KR KR1019960701197A patent/KR100379803B1/ko not_active IP Right Cessation
- 1995-07-10 NZ NZ289170A patent/NZ289170A/en not_active IP Right Cessation
- 1995-07-10 EP EP95924436A patent/EP0719336B1/en not_active Expired - Lifetime
- 1995-07-10 WO PCT/GB1995/001618 patent/WO1996002649A1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003514775A (ja) * | 1999-10-14 | 2003-04-22 | ザ ダウ ケミカル カンパニー | 修飾された植物ウイルス及びその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
HU223078B1 (hu) | 2004-03-29 |
EP0719336B1 (en) | 2006-11-29 |
AU697867B2 (en) | 1998-10-22 |
KR100379803B1 (ko) | 2003-10-04 |
WO1996002649A1 (en) | 1996-02-01 |
BR9506047A (pt) | 1997-08-05 |
DE69535314T2 (de) | 2007-03-08 |
DE69535314D1 (de) | 2007-01-11 |
CN1134174A (zh) | 1996-10-23 |
AU2893495A (en) | 1996-02-16 |
EP0719336A1 (en) | 1996-07-03 |
CA2170412A1 (en) | 1996-02-01 |
NZ289170A (en) | 1997-11-24 |
HUT75088A (en) | 1997-04-28 |
US5958422A (en) | 1999-09-28 |
CZ290484B6 (cs) | 2002-08-14 |
ATE346934T1 (de) | 2006-12-15 |
CA2170412C (en) | 2010-01-12 |
JP3681753B2 (ja) | 2005-08-10 |
SK34296A3 (en) | 1996-07-03 |
GB9414118D0 (en) | 1994-08-31 |
CN1211488C (zh) | 2005-07-20 |
CZ72396A3 (en) | 1996-06-12 |
HUP9600586D0 (en) | 1996-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3681753B2 (ja) | 異種ペプチドのベクターとしての改質植物ウイルス | |
JP3236614B2 (ja) | ベクターとして修正された植物ウイルス | |
Porta et al. | Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides | |
Fernández-Fernández et al. | Development of an antigen presentation system based on plum pox potyvirus | |
NO313917B1 (no) | Antigen-presenterende kapsid med fusert MS2-kappeprotein | |
EP1006782A1 (en) | Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid | |
JPH03280883A (ja) | Rna型ウイルス由来の配列を包含する組換えdnaおよびそれを用いる遺伝子操作方法 | |
US6232099B1 (en) | Method of producing a chimeric protein | |
CA2414396A1 (en) | Production of vaccines using transgenic plants | |
US20030186431A1 (en) | Rabbit hemorrhagic disease vaccine and antigens | |
WO1998056933A1 (en) | Polypeptide presentation system | |
WO1992014489A1 (en) | Poliovirus-based vaccines | |
KR20020066048A (ko) | 단일쇄 rna 재조합 벡터내 삽입 서열의 유전적안정성을 증가시키는 방법 | |
AU2001295525B2 (en) | Rabbit hemorrhagic disease vaccine and antigens | |
MXPA99011361A (en) | Dna sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same | |
AU2001295525A1 (en) | Rabbit hemorrhagic disease vaccine and antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040803 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041102 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A133 Effective date: 20050317 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050317 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050419 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050519 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090527 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100527 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110527 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |